Amneal Pharmaceuticals (AMRX) Finished Goods (2017 - 2020)

Amneal Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $222.2 million for Q1 2020.

• On a quarterly basis, Finished Goods changed N/A year-over-year to $222.2 million in Q1 2020; TTM through Mar 2020 was $222.2 million, a N/A change from a year earlier, with the FY2019 full-year figure at $150.7 million, down 31.93% from the prior year.
• Finished Goods climbed to $222.2 million in Q1 2020 per AMRX's latest filing, from $150.7 million in the prior quarter.
• Across five years, Finished Goods topped out at $250.6 million in Q2 2018 and bottomed at $105.8 million in Q4 2017.
• The 4-year median for Finished Goods is $208.7 million (2018), against an average of $193.7 million.
• Across the five-year window, Finished Goods surged 109.19% in 2018 and plunged 31.93% in 2019, its largest moves.
• Year by year, Finished Goods stood at $105.8 million in 2017, then surged by 109.19% to $221.4 million in 2018, then tumbled by 31.93% to $150.7 million in 2019, then jumped by 47.4% to $222.2 million in 2020.
• Per Business Quant, the three latest AMRX Finished Goods figures stand at $222.2 million (Q1 2020), $150.7 million (Q4 2019), and $168.2 million (Q3 2019).